United States· US:84381-110_54d1f634-8cd7-78c6-e063-6394a90aa9fd
RAPIBLYK
A landiolol product containing landiolol hydrochloride, registered in United States by AOP Orphan Pharmaceuticals GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Landiolol is registered in 15 of 19 countries.
Countries holding a registration under ATC C07AB14 (landiolol), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Landiolol · ATC C07AB14
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LANDIOLOL HYDROCHLORIDE
- Manufacturer
- AOP Orphan Pharmaceuticals GmbH
- Country
- United States (US)
- ATC code
- C07AB14
- ATC class
- Landiolol
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1184381-110-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Landiolol in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- Japanランジオロール塩酸塩小野薬品工業
- CzechiaRAPIBLOCAmomed Pharma GmbH, Vídeň
- NetherlandsLandiolol Hydrochloride Orpha-Devel 300 mg poeder voor oplossing voor infusieOrpha Devel Handels-und Vertriebs GmbH
- FranceRAPIBLOC 20 mg/2 ml, solution à diluer injectableAMOMED PHARMA (AUTRICHE)
- SwedenRapibloc 10 mg/ml Koncentrat till injektionsvätska, lösningAmomed Pharma GmbH
- IrelandRapibloc 300 mg powder for solution for infusionOrpha-Devel Handels und Vertriebs GmbH
- NorwayRaplocAmomed Pharma GmbH
- PolandRunrapiqAmomed Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Rapibloc
- Belgium · Runrapiq
- Bulgaria · Рапиблок
- Cyprus · Rapibloc
- Czechia · Rapibloc
- Germany · Rapibloc
- Denmark · Rapibloc
- Estonia · Raploc
- Spain · Rapibloc
- Finland · Rapibloc
- France · Rapibloc
- Greece · Rapibloc
- Croatia · Rapibloc
- Hungary · Rapibloc
- Ireland · Rapibloc
- Italy · Landiobloc
- Lithuania · Raploc
- Latvia · Raploc
- Netherlands · Landiolol Hydrochloride Orpha-Devel, Rapibloc
- Norway · Raploc
- Poland · Runrapiq
- Portugal · Rapibloc
- Romania · Rapibloc
- Sweden · Rapibloc
- Slovenia · Rapibloc
- Slovakia · Rapibloc
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1acb7c5f-58ff-4348-b606-3890ba8dcc2a GET /v1/drugs/1acb7c5f-58ff-4348-b606-3890ba8dcc2a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "280",
"substance": "LANDIOLOL HYDROCHLORIDE",
"productndc": "84381-110",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA217202",
"marketing_category": "NDA"
}See everything about landiolol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.